Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Revlimid 5 mg Capsules Special Use-results Surveillance (All-case Surveillance)

NCT02921802 is registered in ClinicalTrials.gov with Celgene as lead sponsor.

NCT NCT02921802
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02921802 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Revlimid 5 mg Capsules Special Use-results Surveillance (All-case Surveillance)
Lead sponsor
Celgene
Phase
Observational
Overall status
Completed
Start date
July 20, 2010
Completion date
March 29, 2013
Enrollment
4,626 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma, myelodysplastic syndromes